5,448 reports of this reaction
1.9% of all ADALIMUMAB AATY reports
#3 most reported adverse reaction
RHEUMATOID ARTHRITIS is the #3 most commonly reported adverse reaction for ADALIMUMAB AATY, manufactured by CELLTRION USA, Inc.. There are 5,448 FDA adverse event reports linking ADALIMUMAB AATY to RHEUMATOID ARTHRITIS. This represents approximately 1.9% of all 280,977 adverse event reports for this drug.
Patients taking ADALIMUMAB AATY who experience rheumatoid arthritis should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
RHEUMATOID ARTHRITIS is a less commonly reported adverse event for ADALIMUMAB AATY, but still significant enough to appear in the safety profile.
In addition to rheumatoid arthritis, the following adverse reactions have been reported for ADALIMUMAB AATY:
The following drugs have also been linked to rheumatoid arthritis in FDA adverse event reports:
RHEUMATOID ARTHRITIS has been reported as an adverse event in 5,448 FDA reports for ADALIMUMAB AATY. This does not prove causation, but indicates an association observed in post-market surveillance data.
RHEUMATOID ARTHRITIS accounts for approximately 1.9% of all adverse event reports for ADALIMUMAB AATY, making it one of the most commonly reported side effect.
If you experience rheumatoid arthritis while taking ADALIMUMAB AATY, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.